Literature DB >> 29444348

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.

A Calcagno1, C Pinnetti2, A De Nicolò1, E Scarvaglieri1, M Gisslen3, M Tempestilli2, A D'Avolio1, V Fedele2, G Di Perri1, A Antinori2, S Bonora1.   

Abstract

Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml-1 , P = 0.038 and 123 vs. 49 ng ml-1 , P = 0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  abacavir; age; central nervous system; cerebrospinal fluid; pharmacokinetics; protease inhibitors

Mesh：

Substances：

Year:  2018        PMID： 29444348      PMCID： PMC5980549          DOI： 10.1111/bcp.13552

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  12 in total

1.  The brain entry of HIV-1 protease inhibitors is facilitated when used in combination.

Authors:  Catia Marzolini; Rita Mueller; Xiaochun Li-Blatter; Manuel Battegay; Anna Seelig
Journal:  Mol Pharm       Date:  2013-05-08       Impact factor: 4.939

2.  UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.

Authors:  Marco Simiele; Alessandra Ariaudo; Amedeo De Nicolò; Fabio Favata; Martina Ferrante; Chiara Carcieri; Stefano Bonora; Giovanni Di Perri; Antonio De Avolio
Journal:  J Pharm Biomed Anal       Date:  2017-02-03       Impact factor: 3.935

3.  External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients.

Authors:  H Reiber
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

4.  Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

Authors:  Andrea Antinori; Carlo Federico Perno; Maria Letizia Giancola; Federica Forbici; Giuseppe Ippolito; Richard M Hoetelmans; Stephen C Piscitelli
Journal:  Clin Infect Dis       Date:  2005-11-10       Impact factor: 9.079

5.  Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.

Authors:  Rolf Toornvliet; Bart N M van Berckel; Gert Luurtsema; Mark Lubberink; Albert A Geldof; Tessa M Bosch; Ruud Oerlemans; Adriaan A Lammertsma; Eric J F Franssen
Journal:  Clin Pharmacol Ther       Date:  2006-06       Impact factor: 6.875

Review 6.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.

Authors:  Edmund V Capparelli; Scott L Letendre; Ronald J Ellis; Parul Patel; Diane Holland; J Allen McCutchan
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV.

Authors:  Edward R Hammond; Rosa M Crum; Glenn J Treisman; Shruti H Mehta; Christina M Marra; David B Clifford; Susan Morgello; David M Simpson; Benjamin B Gelman; Ronald J Ellis; Igor Grant; Scott L Letendre; Justin C McArthur
Journal:  Am J Epidemiol       Date:  2014-06-24       Impact factor: 4.897

9.  Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

Authors:  Matteo Vassallo; Jacques Durant; Virginie Biscay; Christine Lebrun-Frenay; Brigitte Dunais; Muriel Laffon; Alexandra Harvey-Langton; Jacqueline Cottalorda; Michel Ticchioni; Helene Carsenti; Christian Pradier; Pierre Dellamonica
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

10.  ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

Authors:  Scott L Letendre; Anthony M Mills; Karen T Tashima; Deborah A Thomas; Sherene S Min; Shuguang Chen; Ivy H Song; Stephen C Piscitelli
Journal:  Clin Infect Dis       Date:  2014-06-18       Impact factor: 9.079
View more
  1 in total

1.  Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.

Authors:  A Calcagno; C Pinnetti; A De Nicolò; E Scarvaglieri; M Gisslen; M Tempestilli; A D'Avolio; V Fedele; G Di Perri; A Antinori; S Bonora
Journal:  Br J Clin Pharmacol       Date:  2018-03-15       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.